Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Summary

This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three weeks of a four week cycle in patients with advanced solid tumors.

Timeline

Start

2007-07

Primary completion

2008-04

Completion

2008-12

Outcome

Outcome not reported

Stopped: “Modified dose schedule presented no advantage over previously studied schedule”

Drugs

Indications